DAX25.389 +0,5%Est506.003 +0,1%MSCI World4.343 -0,1%Top 10 Crypto12,17 +1,1%Nas23.671 +0,8%Bitcoin77.353 -1,0%Euro1,1692 +0,5%Öl63,16 +0,2%Gold4.608 +2,2%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 NVIDIA 918422 Novo Nordisk A3EU6F Deutsche Telekom 555750 Bayer BAY001 Allianz 840400 TKMS thyssenkrupp Marine Systems TKMS00 DroneShield A2DMAA Amazon 906866 BASF BASF11 RENK RENK73 Siemens Energy ENER6Y Lufthansa 823212 Volkswagen (VW) vz. 766403 Infineon 623100
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX etwas höher -- US-Ölkonzerne vor Investments in Venezuela -- Eli Lilly plant wohl Abivax-Übernahme -- Novo Nordisk, Goldrekord, Rüstungsaktien, Amazon, DroneShield, Airbus, BYD im Fokus
Top News
Tesla-Aktie 2026: Warum Analysten trotz Kursrally im Jahr 2025 zur Vorsicht mahnen Tesla-Aktie 2026: Warum Analysten trotz Kursrally im Jahr 2025 zur Vorsicht mahnen
Die besten CFD-Trading-Apps für Smartphones 2025 Die besten CFD-Trading-Apps für Smartphones 2025
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Eli Lilly Aktie

Kaufen
Verkaufen
Eli Lilly Aktien-Sparplan
910,00 EUR -4,40 EUR -0,48 %
STU
1.063,70 USD -21,45 USD -1,98 %
vorbörslich
BTT
Eli Lilly jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.860,33 Mrd. EUR

KGV65,91Div. Rendite0,67%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN858560

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS5324571083

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolLLY

Eli Lilly Aktien News

DatumMeistgelesen
BenzingaThis Is What Whales Are Betting On Eli Lilly
MotleyFool3 Reasons I Bought Novo Nordisk Stock Instead of Eli Lilly
ZacksEli Lilly (LLY) Beats Stock Market Upswing: What Investors Need to Know
PR NewswireFDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease
EN, Eli LillyFDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease
BenzingaOptions Corner: Bullish Traders Eye Eli Lilly As Market Signals Hint At A Turnaround
MotleyFoolBetter Growth Buy: Eli Lilly vs. Viking Therapeutics
MotleyFoolThis GLP-1 Stock's Bad News Could Be a Big Win for Eli Lilly and Novo Nordisk
ZacksHere is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
EN, Eli LillyFDA approves updated label for Lilly’s Amyvid (florbetapir F 18 injection) to support diagnosis of Alzheimer’s disease in patients
MotleyFool3 Reasons to Buy Eli Lilly Stock Like There's No Tomorrow
BenzingaNovo's India Move Could Reshape The Weight-Loss Drug War With Eli Lilly
ZacksEli Lilly (LLY) Surpasses Market Returns: Some Facts Worth Knowing
PR NewswireLilly declares third-quarter 2025 dividend
EN, Eli LillyLilly declares third-quarter 2025 dividend
EN, Eli LillyLilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials
PR NewswireLilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials
PR NewswireLilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Me...
BenzingaForecasting The Future: 7 Analyst Projections For Eli Lilly
ZacksEli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
MarketWatchThis one-and-done heart-disease treatment just got a $1.3 billion endorsement from Eli Lilly
BenzingaEli Lilly Expands Into Gene Editing With Verve Therapeutics Acquisition
PR NewswireLilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
EN, Eli LillyLilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
Financial TimesEli Lilly strikes deal to buy Crispr gene-editing biotech Verve
ZacksEli Lilly (LLY) Stock Dips While Market Gains: Key Facts
BenzingaEli Lilly Launches Flat Pricing For Zepbound, Capping Monthly Cost At $499
ZacksThe Zacks Analyst Blog Highlights Eli Lilly, Home Depot, SAP and Natural Resource Partners
PR NewswireLilly to offer all approved doses of Zepbound (tirzepatide) single-dose vials through LillyDirect Self Pay Pharmacy Solutions
EN, Eli LillyLilly to offer all approved doses of Zepbound (tirzepatide) single-dose vials through LillyDirect Self Pay Pharmacy Solutions
MotleyFoolEli Lilly Just Made Another Move to Dominate the Weight Loss Market: Should You Buy the Stock?
ZacksTop Analyst Reports for Eli Lilly, Home Depot & SAP
Benzinga$1000 Invested In Eli Lilly 5 Years Ago Would Be Worth This Much Today
BenzingaZepbound Put Eli Lilly On Top — Now Its Next Big Move Could Supercharge The Stock
BenzingaEli Lilly Inks Pact With Juvena Therapeutics To Develop Muscle-Boosting Drugs
MotleyFoolShould You Buy Eli Lilly Stock Before June 22?
ZacksEli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Financial TimesBiotech behind Eli Lilly obesity pill aims for new standard of care
MotleyFoolShould You Invest $1,000 in Eli Lilly today?
BenzingaMounjaro Maker Eli Lilly Taps Swedish Firm Camurus To Target Long-Acting Obesity Market In $870-Million Deal

Eli Lilly News

Eli Lilly News: auf dieser Seite finden Sie alle Eli Lilly News und Nachrichten zur Eli Lilly Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Eli Lilly News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Eli Lilly News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.